Published in Neuropharmacology on January 29, 2013
The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals. Adv Pharmacol (2014) 0.90
LSD1n is an H4K20 demethylase regulating memory formation via transcriptional elongation control. Nat Neurosci (2015) 0.88
Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice. Psychopharmacology (Berl) (2013) 0.84
Altered emotionality and neuronal excitability in mice lacking KCTD12, an auxiliary subunit of GABAB receptors associated with mood disorders. Transl Psychiatry (2015) 0.81
Athina Markou's contributions to treatment development for mental illnesses: a perspective. Psychopharmacology (Berl) (2016) 0.81
Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation. Neuropharmacology (2013) 0.80
Modulation of anxiety and fear via distinct intrahippocampal circuits. Elife (2016) 0.79
Effects of acute administration of the GABA(B) receptor agonist baclofen on behavioral flexibility in rats. Psychopharmacology (Berl) (2016) 0.78
Mouse hippocampal GABAB1 but not GABAB2 subunit-containing receptor complex levels are paralleling retrieval in the multiple-T-maze. Front Behav Neurosci (2015) 0.75
The GABA(B) receptor positive modulator BHF177 attenuated anxiety, but not conditioned fear, in rats. Neuropharmacology (2015) 0.75
The role of GABAB receptors in the vestibular oculomotor system in mice. Behav Brain Res (2016) 0.75
Neurobiology of Pavlovian fear conditioning. Annu Rev Neurosci (2001) 6.17
GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature (1998) 5.03
GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature (1998) 4.33
Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev (2004) 3.53
A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav (1996) 3.19
Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov (2002) 2.85
A new benzodiazepine pharmacology. J Pharmacol Exp Ther (2002) 2.75
Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron (2006) 2.53
The neurobiology and control of anxious states. Prog Neurobiol (2003) 2.48
GABAB receptors and their significance in mammalian pharmacology. Trends Pharmacol Sci (1989) 2.22
Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci (2005) 1.84
Electrophysiology of GABAA and GABAB receptor subtypes. Trends Neurosci (1988) 1.80
Neurobiology of addiction. Toward the development of new therapies. Ann N Y Acad Sci (2000) 1.73
Animal models of anxiety: an ethological perspective. Braz J Med Biol Res (1997) 1.73
Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology (2004) 1.72
GABA receptor mechanisms in the central nervous system. Prog Neurobiol (1991) 1.68
Endogenous anxiety and stress responses in water maze and Barnes maze spatial memory tasks. Behav Brain Res (2008) 1.51
Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther (2004) 1.45
Allosteric modulation of G-protein coupled receptors. Eur J Pharm Sci (2004) 1.33
Molecular diversity, trafficking and subcellular localization of GABAB receptors. Pharmacol Ther (2006) 1.30
GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend (2002) 1.27
Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev (2008) 1.26
The age of anxiety: role of animal models of anxiolytic action in drug discovery. Br J Pharmacol (2011) 1.25
Neuropharmacology of amino acid inhibitory transmitters. Annu Rev Pharmacol Toxicol (1978) 1.20
Assessment of spatial memory in mice. Life Sci (2010) 1.20
The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines. Eur J Pharmacol (2003) 1.12
GABAergic influences on plus-maze behaviour in mice. Psychopharmacology (Berl) (1996) 1.09
Specific reduction of alcohol's motivational properties by the positive allosteric modulator of the GABAB receptor, GS39783--comparison with the effect of the GABAB receptor direct agonist, baclofen. Alcohol Clin Exp Res (2008) 1.09
Baclofen, a selective GABAB receptor agonist, dose-dependently impairs spatial learning in rats. Pharmacol Biochem Behav (1996) 1.08
Reduction of alcohol's reinforcing and motivational properties by the positive allosteric modulator of the GABA(B) receptor, BHF177, in alcohol-preferring rats. Alcohol Clin Exp Res (2009) 1.08
Positive modulation of GABA(B) receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats. J Pharmacol Exp Ther (2008) 1.08
Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur J Pharmacol (1993) 1.07
GABAB receptors in reward processes. Adv Pharmacol (2010) 1.06
Post-training systemic and intra-amygdala administration of the GABA-B agonist baclofen impairs retention. Behav Neural Biol (1989) 1.05
Differential expression of gamma-aminobutyric acid type B receptor-1a and -1b mRNA variants in GABA and non-GABAergic neurons of the rat brain. J Comp Neurol (2000) 1.03
The GABAB receptor-positive modulator GS39783 and the GABAB receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: intracranial self-stimulation studies in the rat. Neuropsychopharmacology (2005) 1.02
gamma-aminobutyric acid type B receptor splice variant proteins GBR1a and GBR1b are both associated with GBR2 in situ and display differential regional and subcellular distribution. J Biol Chem (1999) 1.02
Opposite effects of GABAB receptor antagonists on absences and convulsive seizures. Eur J Pharmacol (1997) 1.01
Reducing effect of the positive allosteric modulator of the GABA(B) receptor, GS39,783, on alcohol self-administration in alcohol-preferring rats. Psychopharmacology (Berl) (2007) 1.00
GABAergic mechanisms of analgesia: an update. Pharmacol Biochem Behav (1987) 0.98
Syntheses and optimization of new GS39783 analogues as positive allosteric modulators of GABA B receptors. Bioorg Med Chem Lett (2007) 0.98
GABA(B) receptor-positive modulation decreases selective molecular and behavioral effects of cocaine. Neuropsychopharmacology (2006) 0.97
Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome. J Pharmacol Exp Ther (2011) 0.96
Evaluation of the anxiolytic-like profile of the GABAB receptor positive modulator CGP7930 in rodents. Neuropharmacology (2008) 0.96
Effects of ethanol and GABAB drugs on working memory in C57BL/6J and DBA/2J mice. Psychopharmacology (Berl) (2004) 0.94
Alternative approaches to analgesia: baclofen as a model compound. Br J Pharmacol (1975) 0.93
Effects of GABAB receptor ligands in animal tests of depression and anxiety. Pharmacol Rep (2008) 0.93
GABAB receptor-positive modulation-induced blockade of the rewarding properties of nicotine is associated with a reduction in nucleus accumbens DeltaFosB accumulation. J Pharmacol Exp Ther (2007) 0.93
Animal models of anxiety and anxiolytic drug action. Curr Top Behav Neurosci (2010) 0.93
Repeated administration of the GABAB receptor positive modulator BHF177 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine seeking in rats. Psychopharmacology (Berl) (2010) 0.92
Anticonvulsant-like actions of baclofen in the rat hippocampal slice. Br J Pharmacol (1983) 0.89
A comparison of the antinociceptive responses to the GABA-receptor agonists THIP and baclofen. Neuropharmacology (1985) 0.89
GABAB receptors and depression. Current status. Adv Pharmacol (2010) 0.88
Contextual fear conditioning and baseline startle responses in the rat fear-potentiated startle test: a comparison of benzodiazepine/gamma-aminobutyric acid-A receptor agonists. Behav Pharmacol (2000) 0.87
GABA(A) but not GABA(B) receptor stimulation induces antianxiety profile in rats. Pharmacol Biochem Behav (2001) 0.87
Influence of benzodiazepine binding site ligands on fear-conditioned contextual memory. Eur J Pharmacol (2001) 0.86
Effects of GABAB receptor ligands in rodent tests of anxiety-like behavior. Pharmacol Rep (2008) 0.86
The GABA(B) receptor antagonist CGP36742 attenuates the baclofen- and scopolamine-induced deficit in Morris water maze task in rats. Brain Res (1997) 0.86
The relationship between pain sensitivity and conditioned fear response in rats. Acta Neurobiol Exp (Wars) (2010) 0.84
Clinical potential of GABAB receptor modulators. CNS Drug Rev (2005) 0.84
Influence of beta-adrenoceptor agonists and antagonists on baclofen-induced memory impairment in mice. Behav Pharmacol (2004) 0.84
The GABAB receptor and recognition memory: possible modulation of its behavioral effects by the nitrergic system. Neuroscience (2003) 0.83
Baclofen produces dose-related working memory impairments after intraseptal injection. Behav Neural Biol (1994) 0.83
GABAergic drugs and conflict behavior in the rat: lack of similarities with the actions of benzodiazepines. Naunyn Schmiedebergs Arch Pharmacol (1991) 0.83
Baclofen analgesia: involvement of the GABAergic system. Pharmacol Res (2002) 0.82
Selective effects of triazolam on memory for emotional, relative to neutral, stimuli: differential effects on gist versus detail. Behav Neurosci (2003) 0.82
Both GABA(B) receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats. Eur J Pharmacol (2011) 0.82
Strain-dependent effects of post-training GABA receptor agonists and antagonists on memory storage in mice. Psychopharmacology (Berl) (1993) 0.81
The modified Geller-Seifter test in rats was insensitive to GABAB receptor positive modulation or blockade, or 5-HT1A receptor activation. Behav Brain Res (2009) 0.81
Bi-directional effect of increasing doses of baclofen on reinforcement learning. Front Behav Neurosci (2011) 0.81
Drugs, sweat, and fears: a comparison of the effects of diazepam and methylphenidate on fear conditioning. Psychopharmacology (Berl) (2006) 0.80
GABAB receptor antagonists: potential new anti-absence drugs. J Neural Transm Suppl (1992) 0.80
Interactions between angiotensin II and baclofen in shuttle-box and passive avoidance performance. Neuropeptides (1988) 0.80
The value of genetic and pharmacological approaches to understanding the complexities of GABA(A) receptor subtype functions: the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav (2008) 0.79
Effects of post-training administration of (-)-baclofen and chlordiazepoxide on memory retention in ICRC Swiss mice: interactions with GABAA and GABAB receptor antagonists. Pharmacol Toxicol (1993) 0.78
Prevention of drug-induced memory impairment by immunopharmacotherapy. J Med Chem (2008) 0.78
Effects of psychoactive drugs in the Vogel conflict test in mice. Jpn J Pharmacol (1999) 0.78
Altered emotionality leads to increased pain tolerance in amyloid beta (Abeta1-40) peptide-treated mice. Behav Brain Res (2010) 0.77
Six decades of GABA. Biochem Pharmacol (2004) 0.77
A technique for the investigation of some effects of psychotropic and analgesic drugs on relfexive behavior in the rat. Rep US Army Med Res Lab (1961) 0.76
Direct evidence for mediation of an anticonflict effect of baclofen by GABAb receptors. Pharmacol Biochem Behav (1992) 0.76
GABA-B receptor activation and conflict behaviour. Life Sci (1988) 0.76
Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J Am Chem Soc (2003) 5.34
Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci (2002) 4.02
Analysis and optimization of copper-catalyzed azide-alkyne cycloaddition for bioconjugation. Angew Chem Int Ed Engl (2009) 3.81
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
Enhanced alcohol self-administration after intermittent versus continuous alcohol vapor exposure. Alcohol Clin Exp Res (2004) 3.19
Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. Alcohol Clin Exp Res (2002) 3.11
Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew Chem Int Ed Engl (2002) 3.06
Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci U S A (2005) 3.05
Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev (2004) 2.97
Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. Nat Neurosci (2002) 2.83
Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci (2006) 2.74
Mechanism of the ligand-free CuI-catalyzed azide-alkyne cycloaddition reaction. Angew Chem Int Ed Engl (2005) 2.62
The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci (2011) 2.36
"On water": unique reactivity of organic compounds in aqueous suspension. Angew Chem Int Ed Engl (2005) 2.21
Increased drinking during withdrawal from intermittent ethanol exposure is blocked by the CRF receptor antagonist D-Phe-CRF(12-41). Alcohol Clin Exp Res (2007) 2.19
Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. J Neurosci (2004) 2.13
The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry (2008) 2.08
Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology (2006) 2.05
Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab (2009) 2.00
Primary aldosteronism in hypertensive patients: clinical implications and target therapy. Eur J Clin Invest (2014) 1.99
The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci (2004) 1.90
Ethanol augments GABAergic transmission in the central amygdala via CRF1 receptors. Science (2004) 1.90
Discovery and characterization of catalysts for azide-alkyne cycloaddition by fluorescence quenching. J Am Chem Soc (2004) 1.89
Transcription factor MEF2C influences neural stem/progenitor cell differentiation and maturation in vivo. Proc Natl Acad Sci U S A (2008) 1.87
Labeling live cells by copper-catalyzed alkyne--azide click chemistry. Bioconjug Chem (2010) 1.86
Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci (2007) 1.85
Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconjug Chem (2005) 1.84
The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) (2003) 1.83
Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol (2003) 1.81
Increased motivation for self-administered cocaine after escalated cocaine intake. Neuroreport (2003) 1.73
Ligand-accelerated Cu-catalyzed azide-alkyne cycloaddition: a mechanistic report. J Am Chem Soc (2007) 1.72
A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci U S A (2005) 1.72
Stress enhancement of craving during sobriety: a risk for relapse. Alcohol Clin Exp Res (2005) 1.71
Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem Biol (2007) 1.70
Label-free quantification of membrane-ligand interactions using backscattering interferometry. Nat Biotechnol (2011) 1.67
Natural supramolecular building blocks. Wild-type cowpea mosaic virus. Chem Biol (2002) 1.64
Viral MRI contrast agents: coordination of Gd by native virions and attachment of Gd complexes by azide-alkyne cycloaddition. Chem Commun (Camb) (2007) 1.63
Inhibitors of HIV-1 protease by using in situ click chemistry. Angew Chem Int Ed Engl (2006) 1.63
Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. Pharmacol Biochem Behav (2007) 1.63
Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc Natl Acad Sci U S A (2009) 1.60
Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem (2011) 1.60
Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1. J Virol (2006) 1.59
NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology (2008) 1.57
Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict Sci Clin Pract (2011) 1.57
Tailored ligand acceleration of the Cu-catalyzed azide-alkyne cycloaddition reaction: practical and mechanistic implications. J Am Chem Soc (2010) 1.56
Crosslinking of and coupling to viral capsid proteins by tyrosine oxidation. Chem Biol (2004) 1.55
Designing facial amphiphiles for the stabilization of integral membrane proteins. Angew Chem Int Ed Engl (2007) 1.55
Unnatural amino acid incorporation into virus-like particles. Bioconjug Chem (2008) 1.54
Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology (2005) 1.53
Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J Control Release (2007) 1.53
The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology (Berl) (2004) 1.51
Benzimidazole and related ligands for Cu-catalyzed azide-alkyne cycloaddition. J Am Chem Soc (2007) 1.50
Icosahedral virus particles as addressable nanoscale building blocks. Angew Chem Int Ed Engl (2002) 1.49
Glial ephrin-A3 regulates hippocampal dendritic spine morphology and glutamate transport. Proc Natl Acad Sci U S A (2009) 1.49
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) (2003) 1.49
Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol Psychiatry (2010) 1.48
Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology (Berl) (2001) 1.47
Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology (Berl) (2004) 1.47
Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction. Psychopharmacology (Berl) (2006) 1.45
Nicotine withdrawal in adolescent and adult rats. Ann N Y Acad Sci (2004) 1.44
Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules (2003) 1.42
Plasma clearance of bacteriophage Qbeta particles as a function of surface charge. J Am Chem Soc (2008) 1.41
The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci (2006) 1.40
Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. Clin Biochem (2006) 1.39
In situ click chemistry: probing the binding landscapes of biological molecules. Chem Soc Rev (2010) 1.38
Thiol-selective fluorogenic probes for labeling and release. J Am Chem Soc (2009) 1.36
Corticotropin-releasing factor receptor-2-deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold. Endocrinology (2003) 1.34
Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle. J Virol (2008) 1.34
Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology (2005) 1.34
Direct human cartilage repair using three-dimensional bioprinting technology. Tissue Eng Part A (2012) 1.33
Multivalent, bifunctional dendrimers prepared by click chemistry. Chem Commun (Camb) (2005) 1.32
Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems. J Neurosci (2005) 1.31
Extended access to nicotine self-administration leads to dependence: Circadian measures, withdrawal measures, and extinction behavior in rats. J Pharmacol Exp Ther (2006) 1.30
Functional virus-based polymer-protein nanoparticles by atom transfer radical polymerization. J Am Chem Soc (2011) 1.30
Natural supramolecular building blocks. Cysteine-added mutants of cowpea mosaic virus. Chem Biol (2002) 1.29
Laparoscopic surgery for adrenal tumors. A retrospective analysis. Hormones (Athens) (2006) 1.29
Chemical modification of viruses and virus-like particles. Curr Top Microbiol Immunol (2009) 1.28
IL-6 mediated degeneration of forebrain GABAergic interneurons and cognitive impairment in aged mice through activation of neuronal NADPH oxidase. PLoS One (2009) 1.28
The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl) (2003) 1.28
Core-clickable PEG-branch-azide bivalent-bottle-brush polymers by ROMP: grafting-through and clicking-to. J Am Chem Soc (2010) 1.26
On-virus construction of polyvalent glycan ligands for cell-surface receptors. J Am Chem Soc (2008) 1.26
Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci (2007) 1.25
Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies. CNS Drugs (2008) 1.24
Multivalent display and receptor-mediated endocytosis of transferrin on virus-like particles. Chembiochem (2010) 1.24
5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology (2009) 1.24
Click chemistry: function follows form. Chem Soc Rev (2010) 1.23
The mGluR2 positive allosteric modulator BINA decreases cocaine self-administration and cue-induced cocaine-seeking and counteracts cocaine-induced enhancement of brain reward function in rats. Neuropsychopharmacology (2010) 1.23
Head-to-tail peptide cyclodimerization by copper-catalyzed azide-alkyne cycloaddition. Angew Chem Int Ed Engl (2005) 1.23
Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem Biol (2010) 1.21
Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem Biol (2010) 1.21
Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology (2008) 1.20
Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther (2003) 1.20
Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol Biochem Behav (2005) 1.19
Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res (2002) 1.19
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology (Berl) (2007) 1.18
Microscale NMR screening of new detergents for membrane protein structural biology. J Am Chem Soc (2008) 1.18
Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats. Neuropsychopharmacology (2005) 1.18
Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder. Neuropsychopharmacology (2012) 1.17
Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry (2003) 1.17
Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition? Neurosci Biobehav Rev (2010) 1.17